TRIPLE NEGATIVE BREAST CANCER

This study is testing whether a new drug called ARX788 can help control advanced breast cancer that has a specific low level of a protein called HER2. The drug is given by IV infusion and works by attaching a cancer-killing toxin directly to tumor cells. Researchers will enroll 3…

This study is testing whether injecting a common local anesthetic (levobupivacaine) around the tumor and nearby nerves before breast-conserving surgery can help patients with triple-negative breast cancer. The goal is to see if this simple addition to standard surgery can reduce …

This early-stage trial is testing a personalized cancer vaccine designed to teach a patient's immune system to fight their specific breast cancer. It will be given to 30 people with newly diagnosed triple-negative breast cancer who are already receiving standard chemotherapy and …

This large trial aims to find better ways to control early-stage triple-negative breast cancer, an aggressive form of the disease. It will test if a new combination of two drugs (sacituzumab govitecan and pembrolizumab) works better than standard chemotherapy for patients who sti…

This study is testing whether some patients with early-stage breast cancer who have an exceptional response to chemotherapy can safely avoid surgery. It aims to see if a non-surgical approach leads to similar cancer control as the standard surgery. The trial will enroll 84 patien…

This early-stage study is testing a new type of personalized immune cell therapy called GCAR1 in people with advanced cancers that have stopped responding to standard treatments. The main goal is to find the safest and most effective dose of GCAR1 for patients with specific types…

This large, late-stage trial aims to see if adding the drug pembrolizumab to standard follow-up treatment helps prevent cancer from coming back in people with early triple-negative breast cancer. It will enroll 1,000 patients whose cancer did not completely disappear after initia…

This trial is testing a new combination of three drugs as the first treatment for people with advanced triple-negative breast cancer that tests positive for a marker called PD-L1. The goal is to see if the combination is safe and can shrink tumors and control the cancer. It will …

This study is for women with a specific, aggressive type of early-stage breast cancer (triple-negative). It tests if patients whose cancer disappears completely after powerful drug treatment can safely skip the standard follow-up surgery. The goal is to see if avoiding surgery pr…

This study is testing whether personalized dosing guidelines for people with a specific blood type (Duffy null) can help them better tolerate standard cancer treatments. Researchers will enroll 90 people with multiple myeloma or triple-negative breast cancer to see if these tailo…

This study is testing whether adding a new immunotherapy drug (serplulimab) to standard chemotherapy before surgery helps shrink tumors more effectively in people with triple-negative breast cancer. It will involve about 46 women with early-stage disease to see if this combinatio…

This is the first study in people to test a new drug called ITC-6146RO for patients with advanced or metastatic cancer who have run out of standard treatment options. The main goals are to find a safe dose and see how the body processes the drug. The study will enroll about 102 a…

This study aims to find better treatments for advanced breast cancer by matching therapies to specific tumor characteristics. It will enroll 700 patients whose cancer has progressed after initial treatment. Doctors will analyze tumor markers and assign standard treatments accordi…

This study is testing whether a three-drug combination can help control triple-negative breast cancer that has worsened despite previous immunotherapy. It will enroll 46 women whose cancer has progressed after standard treatments. The approach adds a mast cell stabilizer (cromoly…

This study is testing if freezing a breast tumor (cryoablation) combined with an immunotherapy drug (pembrolizumab) can better train the body's immune system to fight triple-negative breast cancer. It will compare this new approach to standard treatment and freezing alone in 36 w…

This study is testing an artificial intelligence (AI) tool designed to help doctors treat triple-negative breast cancer. The AI analyzes images of a patient's tumor tissue to predict how well they might respond to chemotherapy and their long-term survival chances. The research wi…

This study is testing a new blood test that looks for tiny pieces of cancer DNA in people with early-stage triple negative breast cancer. Researchers want to see if finding this DNA can help predict whether the cancer might come back after treatment. The study will follow 77 pati…

This study is testing whether a new blood test can detect if triple-negative breast cancer is returning earlier than current standard scans. Thirty patients who have finished initial treatment will be randomly assigned to receive either standard follow-up care or standard care pl…